Search research articles
Contact Us
Filters
Showing results (51-60 of 208) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Suzanne Trudel, A Keith Stewart, Zhihua Li, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma
K Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
British Journal of Haematology
|
August 21, 2014
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, et al.
Leukemia & Lymphoma
|
May 13, 2006
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group
Richard Van Der Jagt, K Sue Robinson, Andrew Belch, et al.
Blood
|
March 28, 2012
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Marta Chesi, Geoffrey M Matthews, Victoria M Garbitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2007
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group
Christine I Chen, C Tom Kouroukis, Darrell White, et al.
Transplantation and Cellular Therapy
|
September 23, 2023
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial
Michael Slade, Mark A Fiala, Marie Kirchmeyer, et al.
Frontiers in Oncology
|
February 25, 2022
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Claudio Cerchione, Saad Z Usmani, A Keith Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
European Journal of Haematology
|
May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
Francesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.
Page
of 21
Search research articles
Search
Showing results (51-60 of 208) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Suzanne Trudel, A Keith Stewart, Zhihua Li, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma
K Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
British Journal of Haematology
|
August 21, 2014
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, et al.
Leukemia & Lymphoma
|
May 13, 2006
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group
Richard Van Der Jagt, K Sue Robinson, Andrew Belch, et al.
Blood
|
March 28, 2012
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Marta Chesi, Geoffrey M Matthews, Victoria M Garbitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2007
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group
Christine I Chen, C Tom Kouroukis, Darrell White, et al.
Transplantation and Cellular Therapy
|
September 23, 2023
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial
Michael Slade, Mark A Fiala, Marie Kirchmeyer, et al.
Frontiers in Oncology
|
February 25, 2022
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Claudio Cerchione, Saad Z Usmani, A Keith Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
European Journal of Haematology
|
May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
Francesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.
Page
of 21